Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

530
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
530
MicroRNAs01:22

MicroRNAs

3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

222
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
222

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Down-Regulation of Acyloxyacyl Hydrolase Expression in Alzheimer's Disease Impairs LPS Detoxification and Contributes to Brain Pro-Inflammatory Signaling.

Molecules (Basel, Switzerland)·2026
Same author

Dietary fiber modulates gut microbiota and lipid metabolism ameliorating Alzheimer's pathology in 5xFAD mice.

Scientific reports·2025
Same author

Maresin-like 1 Ameliorates Neuropathology of Alzheimer's Disease in Brains of a Transgenic Mouse Model.

Biomedicines·2025
Same author

Commentary: A tribute to Dr. Paul Berg (1926-2023) American biochemist, Nobel Laureate and discoverer of recombinant DNA technology, vaccine and genetic engineering.

Frontiers in cell and developmental biology·2023
Same author

Higher rates of autism and attention deficit/hyperactivity disorder in American children: Are food quality issues impacting epigenetic inheritance?

World journal of clinical pediatrics·2023
Same author

Endogenous miRNA-Based Innate-Immunity against SARS-CoV-2 Invasion of the Brain.

International journal of molecular sciences·2023

Related Experiment Video

Updated: Jul 25, 2025

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:44

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

544

MicroRNA (miRNA) Complexity in Alzheimer's Disease (AD).

Walter J Lukiw1,2,3,4

  • 1LSU Neuroscience Center, Louisiana State University Health Science Center, New Orleans, LA 70112, USA.

Biology
|June 28, 2023
PubMed
Summary
This summary is machine-generated.

MicroRNAs (miRNAs) are key regulators of gene expression in Alzheimer's disease (AD). Analyzing miRNA signatures in brain tissue offers insights into AD mechanisms and potential RNA-based therapeutics.

Keywords:
Alzheimer’s disease (AD)RNA sequencingbiomarkercircular RNAexosomes (EX)extracellular microvesicles (EMVs)hippocampusinflammatory neurodegenerationlipopolysaccharidemiRNA-146a

More Related Videos

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.2K

Related Experiment Videos

Last Updated: Jul 25, 2025

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
06:44

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

544
Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
09:33

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

8.0K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.2K

Area of Science:

  • Neurobiology
  • Molecular Genetics
  • Neurodegenerative Disorders

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia.
  • The heterogeneity of AD stems from complex molecular-genetic mechanisms in the brain.
  • MicroRNAs (miRNAs) play a crucial role in regulating gene expression within brain cells.

Purpose of the Study:

  • To analyze miRNA populations in Alzheimer's disease (AD) brains.
  • To characterize miRNA abundance, speciation, and complexity in relation to AD.
  • To identify miRNA-based signatures for understanding AD pathogenesis and developing therapeutics.

Main Methods:

  • Analysis of high-quality post-mortem brain tissues from AD patients and age/gender-matched controls.
  • Characterization of free and exosome-bound miRNA species in the human brain and CNS.
  • Review of current research on miRNA signaling complexity in the hippocampal CA1 region of AD brains.

Main Results:

  • Identification of specific miRNA species significantly affected by the AD process.
  • Determination of pathophysiological miRNA-based signatures in AD brains.
  • Consolidation of findings on abundant and affected miRNA species from multiple research laboratories.

Conclusions:

  • miRNA analysis provides valuable molecular-genetic insights into Alzheimer's disease (AD).
  • Pathophysiological miRNA signatures can enhance mechanistic understanding of AD.
  • Findings support the future development of miRNA- and related RNA-based therapeutics for AD.